Affiliation:
1. First Clinical Medical College Shanxi Medical University Taiyuan China
2. Department of Endocrinology First Hospital of Shanxi Medical University Taiyuan China
3. Department of Endocrinology Changzhi Second People's Hospital Changzhi China
Abstract
ABSTRACTAims/IntroductionSerum asprosin is expected to become a screening indicator in early‐stage diabetic heart disease. The relationship between serum asprosin and left ventricular diastolic dysfunction (LVDD) was studied in elderly patients with type 2 diabetes mellitus in the community.Materials and MethodsA total of 252 elderly patients with type 2 diabetes mellitus were recruited from Zhuoma Community Care Station and Chengbei West Street Community Care Service Center in Changzhi City of Shanxi Province from November 2019 to July 2021. Patients were divided into the LVDD group (n = 195) and the non‐LVDD group (n = 57). The t‐test, Mann–Whitney U test, and χ2 test were used to compare indicators between the LVDD group and the non‐LVDD group. Pearson or Spearman correlation analysis was adopted to evaluate the correlation between serum asprosin and other clinical data. Multivariate logistic regression analysis was applied to analyze the influencing factors on LVDD.ResultsCompared with patients without LVDD, patients with LVDD had a higher level of low‐density lipoprotein cholesterol (LDL‐C), fasting blood glucose (FPG), and asprosin, but a lower level of early diastolic movement speed (A) to diastolic movement velocity (E) (E/A). Asprosin was positively associated with waist circumference (WC), body mass index (BMI), creatinine, triglycerides (P < 0.05), and negatively associated with E/A and high density lipoprotein cholesterol HDL‐C (P < 0.05). The risk of LVDD increased with elevated asprosin levels after adjustment for age, systolic blood pressure (SBP), BMI, FPG, and LDL‐C. Compared with patients in the lowest tertile of serum asprosin (<275.25 pg/mL), a serum level of asprosin between 275.25–355.08 pg/mL [OR (95% CI) is 2.368 (1.169–4.796), P < 0.05] and asprosin >355.08 pg/mL [OR (95% CI) is 2.549 (1.275–5.095), P < 0.05] patients have a higher risk of left ventricular diastolic dysfunction.ConclusionsSerum asprosin was positively associated with left ventricular diastolic dysfunction, and the risk of LVDD increased significantly with increased serum levels of asprosin.